Sharekhan's research report on UPL
Weak Q4FY23 results with a 2%/400 bps miss in consolidated revenue/EBITDA margin at Rs. 16,569 crore/18.2%, up/down 4.5%/445 y-o-y due to a decline in post-patent product price, idle capacity costs, and a higher share of low-margin LatAM region. Adjusted PAT of Rs. 821 crore (down 46% y-o-y and 52% below our estimate) was further impacted by higher depreciation and tax rate. North America revenue fell by 14% y-o-y to Rs. 3,009 crore due to steep decline in Glufosinate prices and delayed spring impacted herbicides/insecticides demand. Revenue from LatAM/Europe/India/RoW grew by 11.9%/6.5%/14.7%/5.9% y-o-y. Volume remained muted at +1% y-o-y while product realisation declined by 3% y-o-y and there was positive currency impact of 6% y-o-y. FY23 EBITDA growth of 10% missed guidance of 15-18% due to subdued Q4. FY24 revenue/EBITDA guidance growth of 6-10%/8-12% would also be dependent upon recovery in H2FY24 as oversupply from China would keep product price/margin under check in H1FY24. We thus cut our FY24/FY25 earnings estimate sharply by 24%/16%.
Outlook
Valuation of 11.4x/8.9x FY24E/FY25E EPS seems attractive and thus we maintain a Buy on UPL but with a lower PT of Rs. 880 (to reflect an earnings cut).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.